Steward Partners Investment Advisory LLC acquired a new stake in shares of AstraZeneca plc (NYSE:AZN) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 14,137 shares of the company’s stock, valued at approximately $478,000.
A number of other institutional investors have also recently bought and sold shares of AZN. SG Americas Securities LLC boosted its position in AstraZeneca by 29.8% during the 2nd quarter. SG Americas Securities LLC now owns 25,919 shares of the company’s stock valued at $884,000 after acquiring an additional 5,956 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of AstraZeneca by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 195,965 shares of the company’s stock valued at $6,681,000 after purchasing an additional 11,311 shares during the last quarter. Opus Capital Group LLC purchased a new position in shares of AstraZeneca during the second quarter valued at approximately $202,000. Blair William & Co. IL lifted its holdings in shares of AstraZeneca by 62.3% during the second quarter. Blair William & Co. IL now owns 42,117 shares of the company’s stock valued at $1,436,000 after purchasing an additional 16,174 shares during the last quarter. Finally, BB&T Securities LLC lifted its holdings in shares of AstraZeneca by 5.8% during the second quarter. BB&T Securities LLC now owns 261,141 shares of the company’s stock valued at $8,902,000 after purchasing an additional 14,241 shares during the last quarter. 14.75% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have recently issued reports on AZN. Liberum Capital lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. BNP Paribas upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. BMO Capital Markets reiterated a “buy” rating and set a $38.00 target price on shares of AstraZeneca in a report on Tuesday, November 7th. Citigroup upgraded shares of AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Finally, Sanford C. Bernstein upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $30.00 to $39.00 in a report on Friday, September 22nd. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $34.20.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the business earned $1.32 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. analysts anticipate that AstraZeneca plc will post 1.87 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “14,137 Shares in AstraZeneca plc (AZN) Acquired by Steward Partners Investment Advisory LLC” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/18/14137-shares-in-astrazeneca-plc-azn-acquired-by-steward-partners-investment-advisory-llc.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.